Acute Lymphoblastic Leukemia
Anti‑cancer Drug Venetoclax and/or the Anti‑cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A‑rearranged or KMT2A‑non‑rearranged Leukemia
This phase II trial evaluates the safety and effectiveness of adding venetoclax and/or blinatumomab to standard chemotherapy for the treatment of infants with KMT2A‑R or KMT2A‑G acute lymphoblastic leukemia.
Evidence level: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Related signals
- Acute Myeloid Leukemia Treatment (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf
- Recent advances on blinatumomab for acute lymphoblastic leukemia
- NCT05800210: Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Acute Lymphoblastic Leukemia
- Advancing the Diagnosis of Non‑Hodgkin Lymphoma Through Next‑Generation Sequencing in Developing Countries: An Evaluation of Progress — A Narrative Review
- The Evolving Therapeutic Revolution in Adult Acute Lymphoblastic Leukemia